Brian Conway

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts et al. · New England Journal of Medicine · 2015 · 850 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

Gregory J. Dore, Frederick L. Altice, Alain H. Litwin et al. · Annals of Internal Medicine · 2016 · 363 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

Jason Grebely, Olav Dalgård, Brian Conway et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 292 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14